Artelo Biosciences (NASDAQ:ARTL) is expanding its development pipeline into ophthalmology with a new clinical study evaluating its drug candidate ART27.13 for the treatment of glaucoma. The San ...
Artelo Biosciences (ARTL) stock jumped 40% after announcing a fully-funded glaucoma trial for ART27.13 with Belfast Health and Social Care Trust.
Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ophthalmologyFirst ...
Explore the latest research on glaucoma treatment and the role of immune cells in eye pressure regulation for better outcomes ...
The 2026 Shaffer Research Grants were awarded to Kun-Che Chang, PhD, Shruthi Karnam, PhD, Kate Keller, PhD, Naoki Kiyota, MD, PhD, Gillian McLellan, PhD, Kiyoharu Miyagishima, PhD, Kerstin Nundel, PhD ...
When the eye's drainage system clogs, pressure builds up and causes damage. The pressure can lead to glaucoma and vision loss. New research, published in the journal Immunity, reveals that a ...
New English and Spanish editions of Understanding and Living with Glaucoma and first-ever Spanish audiobook aim to reach high-risk Hispanic ...
Glaucoma develops when fluid inside the eye doesn’t drain properly, causing pressure to build up over time and damage the ...
SAN FRANCISCO--(BUSINESS WIRE)--Glaucoma Research Foundation, a national non-profit organization dedicated to finding a cure for glaucoma, has launched the third phase of its collaborative research ...
A new center coming to UC San Diego, funded by a $20 million donation from philanthropists Hanna and Mark Gleiberman, has its sights set on discovering how to reverse glaucoma. The Hanna and Mark ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results